We are analyzing https://link.springer.com/article/10.1007/s00280-012-2042-4.

Title:
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine | Cancer Chemotherapy and Pharmacology
Description:
Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents. VCR is an M-phase cell cycle-specific anticancer drug with activity that is concentration and exposure duration dependent. The pharmacokinetic profile of standard VCR is described by a bi-exponential elimination pattern with a very fast initial distribution half-life followed by a longer elimination half-life. VCR also has a large volume of distribution, suggesting diffuse distribution and tissue binding. These properties may limit optimal drug exposure and delivery to target tissues as well as clinical utility as a single agent or as an effective component of multi-agent regimens. Vincristine sulfate liposome injection (VSLI), Marqibo®, is a sphingomyelin and cholesterol-based nanoparticle formulation of VCR that was designed to overcome the dosing and pharmacokinetic limitations of standard VCR. VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity. In xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues compared to standard VCR. VSLI recently received accelerated FDA approval for use in adults with advanced, relapsed and refractory Philadelphia chromosome-negative ALL and is in development for untreated adult ALL, pediatric ALL and untreated aggressive NHL. Here, we summarize the nonclinical data for VSLI that support its continued clinical development and recent approval for use in adult ALL.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

vcr, vsli, google, scholar, vincristine, pubmed, cas, article, drug, cancer, activity, tissues, plasma, tumor, dose, cell, liposomes, liposome, standard, total, pharmacokinetic, tumors, human, table, properties, liposomal, distribution, administration, circulation, cells, data, pharmacokinetics, tissue, antitumor, res, clinical, time, mice, models, treatment, anticancer, exposure, profile, delivery, formulation, leukemia, fig, rats, full, demonstrated,

Topics {✒️}

validated lc/ms–ms method refractory philadelphia chromosome-negative radio-labeled mass-balance studies intra-vital microscopy imaging t-lymphocytes characterized primarily article download pdf philadelphia chromosome-negative multi-drug chemotherapeutic regimens meeuwsen-de boer gj surface-modified liposome technologies pink-flowered periwinkle plant longer elimination half-life high-pressure liquid chromatography bi-exponential elimination pattern carrier-mediated anticancer agents drug-resistant tumor models b16/bl6 solid tumours 5 μg protein/mg lipid full size image heavily pre-treated adults extensive distribution half-life 4 mg/m2 administered intravenously sm/chol lipid composition apparent bi-exponential profiles vcr-mediated antitumor activity acute lymphoblastic leukemia human tumor xenograft table 2 cross-species comparison acute lymphoblastic leukaemia cholesterol-based nanoparticle formulation cr/cri rate 0 mg/kg administered q7d × 3 cell cycle dependent ht29 colon carcinoma sm/chol liposomes offer human sclc model enhanced target-tissue accumulation advanced relapsed/refractory leukemia liposome technology–enhanced drugs privacy choices/manage cookies vinca alkaloids–chemotherapeutic agents tumor xenograft models acute lymphocytic leukemia prevents chromosome segregation burnett jp jr radio-labeled drug human tumour models tumor bearing mice human lymphoma model prolonged half-life

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
         description:Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents. VCR is an M-phase cell cycle-specific anticancer drug with activity that is concentration and exposure duration dependent. The pharmacokinetic profile of standard VCR is described by a bi-exponential elimination pattern with a very fast initial distribution half-life followed by a longer elimination half-life. VCR also has a large volume of distribution, suggesting diffuse distribution and tissue binding. These properties may limit optimal drug exposure and delivery to target tissues as well as clinical utility as a single agent or as an effective component of multi-agent regimens. Vincristine sulfate liposome injection (VSLI), Marqibo®, is a sphingomyelin and cholesterol-based nanoparticle formulation of VCR that was designed to overcome the dosing and pharmacokinetic limitations of standard VCR. VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity. In xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues compared to standard VCR. VSLI recently received accelerated FDA approval for use in adults with advanced, relapsed and refractory Philadelphia chromosome-negative ALL and is in development for untreated adult ALL, pediatric ALL and untreated aggressive NHL. Here, we summarize the nonclinical data for VSLI that support its continued clinical development and recent approval for use in adult ALL.
         datePublished:2012-12-05T00:00:00Z
         dateModified:2012-12-05T00:00:00Z
         pageStart:555
         pageEnd:564
         sameAs:https://doi.org/10.1007/s00280-012-2042-4
         keywords:
            Liposome
            Marqibo
            Pharmacokinetics
            Vincristine
            VSLI
            Xenograft
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig5_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:71
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jeffrey A. Silverman
               affiliation:
                     name:Talon Therapeutics Inc.
                     address:
                        name:Talon Therapeutics Inc., South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Steven R. Deitcher
               affiliation:
                     name:Talon Therapeutics Inc.
                     address:
                        name:Talon Therapeutics Inc., South San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
      description:Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors due to its well-defined mechanism of action, demonstrated anticancer activity and its ability to be combined with other agents. VCR is an M-phase cell cycle-specific anticancer drug with activity that is concentration and exposure duration dependent. The pharmacokinetic profile of standard VCR is described by a bi-exponential elimination pattern with a very fast initial distribution half-life followed by a longer elimination half-life. VCR also has a large volume of distribution, suggesting diffuse distribution and tissue binding. These properties may limit optimal drug exposure and delivery to target tissues as well as clinical utility as a single agent or as an effective component of multi-agent regimens. Vincristine sulfate liposome injection (VSLI), Marqibo®, is a sphingomyelin and cholesterol-based nanoparticle formulation of VCR that was designed to overcome the dosing and pharmacokinetic limitations of standard VCR. VSLI was developed to increase the circulation time, optimize delivery to target tissues and facilitate dose intensification without increasing toxicity. In xenograft studies in mice, VSLI had a higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues compared to standard VCR. VSLI recently received accelerated FDA approval for use in adults with advanced, relapsed and refractory Philadelphia chromosome-negative ALL and is in development for untreated adult ALL, pediatric ALL and untreated aggressive NHL. Here, we summarize the nonclinical data for VSLI that support its continued clinical development and recent approval for use in adult ALL.
      datePublished:2012-12-05T00:00:00Z
      dateModified:2012-12-05T00:00:00Z
      pageStart:555
      pageEnd:564
      sameAs:https://doi.org/10.1007/s00280-012-2042-4
      keywords:
         Liposome
         Marqibo
         Pharmacokinetics
         Vincristine
         VSLI
         Xenograft
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-012-2042-4/MediaObjects/280_2012_2042_Fig5_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:71
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jeffrey A. Silverman
            affiliation:
                  name:Talon Therapeutics Inc.
                  address:
                     name:Talon Therapeutics Inc., South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Steven R. Deitcher
            affiliation:
                  name:Talon Therapeutics Inc.
                  address:
                     name:Talon Therapeutics Inc., South San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:71
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Talon Therapeutics Inc.
      address:
         name:Talon Therapeutics Inc., South San Francisco, USA
         type:PostalAddress
      name:Talon Therapeutics Inc.
      address:
         name:Talon Therapeutics Inc., South San Francisco, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jeffrey A. Silverman
      affiliation:
            name:Talon Therapeutics Inc.
            address:
               name:Talon Therapeutics Inc., South San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Steven R. Deitcher
      affiliation:
            name:Talon Therapeutics Inc.
            address:
               name:Talon Therapeutics Inc., South San Francisco, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Talon Therapeutics Inc., South San Francisco, USA
      name:Talon Therapeutics Inc., South San Francisco, USA

External Links {🔗}(164)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Particles.js
Prism.js

CDN Services {📦}

Crossref

5.33s.

LINK . SPRINGER . COM {}